These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11697843)

  • 21. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
    Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
    Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
    [No Abstract]   [Full Text] [Related]  

  • 22. Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size.
    Kleiman DA; Finnerty B; Beninato T; Zarnegar R; Nandakumar G; Fahey TJ; Lee SW
    Dis Colon Rectum; 2015 Dec; 58(12):1137-43. PubMed ID: 26544810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion.
    Lefebvre S; De Paepe L; Abs R; Rahier J; Selvais P; Maiter D
    Eur J Endocrinol; 1995 Sep; 133(3):320-4. PubMed ID: 7581949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
    Dham A; Truskinovsky AM; Dudek AZ
    J Thorac Oncol; 2008 Jan; 3(1):94-7. PubMed ID: 18166847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
    Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
    Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
    Katakami N; Matsumoto H; Ishihara K; Umeda B
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide scanning for carcinoid tumours.
    Critchley M
    Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of neuroendocrine tumours.
    Taal BG; Visser O
    Neuroendocrinology; 2004; 80 Suppl 1():3-7. PubMed ID: 15477707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal carcinoid tumours. A population-based study.
    Crocetti E
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):135-7. PubMed ID: 9646193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
    Massimino K; Harrskog O; Pommier S; Pommier R
    J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide.
    Barhoum M; Hutchins L; Fonseca VA
    Am J Med Sci; 1999 Sep; 318(3):203-5. PubMed ID: 10487414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.